Thursday, June 1, 2023
Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.
Health Sciences Clinical Professor of Family Medicine
University of California, Irvine School of Medicine
Irvine, California
This activity has been peer reviewed and the reviewer has no relevant financial relationships.
Physicians - maximum of 0.25 AMA PRA Category 1 Credit(s)™
ABIM Diplomates - maximum of 0.25 ABIM MOC points
Nurses - 0.25 ANCC Contact Hour(s) (0 contact hours are in the area of pharmacology)
Pharmacists - 0.25 Knowledge-based ACPE (0.025 CEUs)
Physician Assistant - 0.25 AAPA hour(s) of Category I credit
IPCE - 0.25 Interprofessional Continuing Education (IPCE) credit
This activity is intended for primary care clinicians, obstetrician gynecologists, infectious disease specialists, pediatricians, nurses, physician assistants, nurse practitioners, pharmacists and other clinicians who treat and manage pregnant women and young children.
The goal of this activity is for learners to be better able to analyze the risk for neurodevelopmental diagnoses early in childhood associated with maternal SARS-CoV-2 infection.
Upon completion of this activity, participants will:
Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.
Health Sciences Clinical Professor of Family Medicine
University of California, Irvine School of Medicine
Irvine, California
This activity has been peer reviewed and the reviewer has no relevant financial relationships.
This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.
Medscape, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 credit™ into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
College of Family Physicians of Canada Mainpro+® participants may claim certified credits for any AMA PRA Category 1 credit(s)™, up to a maximum of 50 credits per five-year cycle. Any additional credits are eligible as non-certified credits. College of Family Physicians of Canada (CFPC) members must log into Mainpro+® to claim this activity.
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Awarded 0.25 contact hour(s) of nursing continuing professional development for RNs and APNs; 0.00 contact hours are in the area of pharmacology.
Medscape designates this continuing education activity for 0.25 contact hour(s) (0.025 CEUs) (Universal Activity Number: JA0007105-0000-23-176-H01-P).
Medscape, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until 5/19/2024. PAs should only claim credit commensurate with the extent of their participation.
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability
and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the
activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.
Follow these steps to earn CME/CE credit*:
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it.
Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print
out the tally as well as the certificates from the CME/CE Tracker.
*The credit that you receive is based on your user profile.
CME / ABIM MOC / CE Released: 5/19/2023
Valid for credit through: 5/19/2024
processing....
Note: The information on the coronavirus outbreak is continually evolving. The content within this activity serves as a historical reference to the information that was available at the time of this publication. We continue to add to the collection of activities on this subject as new information becomes available. It is the policy of Medscape Education to avoid the mention of brand names or specific manufacturers in accredited educational activities. However, manufacturer names related to the approved COVID-19 vaccines are provided in this activity in an effort to promote clarity. The use of manufacturer names should not be viewed as an endorsement by Medscape of any specific product or manufacturer.
Vaccination is an important part of prenatal care to improve the health outcomes of both mothers and infants. The authors of the current study note that previous research has found that maternal infection with viruses such as influenza during pregnancy is associated with negative neurocognitive outcomes in children. A registry-based study found that infection requiring hospitalization during pregnancy was associated with a 30% increase in the risk for autism spectrum disorders (ASD) among offspring. Another study found that any significant maternal infection was associated with higher risks for ASD and depression among offspring, regardless of the severity of the primary infection.
There is limited research into the effects of maternal infection with COVID-19 on neurocognitive outcomes of children. A meta-analysis of 691 children exposed to COVID-19 in utero found no significant impairment in neurocognitive outcomes through 12 months, although fine motor function was impaired in these children compared with in children without COVID-19 exposure.
The authors of the current study further examine the relationship between COVID-19 during pregnancy and cognitive outcomes, with special attention to sex-based differences. Sex-specific differences in the immune response among female and male fetuses have been implicated in the pathogenesis of the gap between boys and girls for outcomes such as ASD and attention-deficit/hyperactivity disorder.
Boys born to mothers with COVID-19 could face brain development issues at a rate twice that of others, a new study found.
The study involved more than 18,000 children born at 8 hospitals in Massachusetts. Almost 900 of them were born to women who had COVID-19 while pregnant.
The male babies were more prone to a range of developmental disorders in the first 18 months of life, says the study, which was published in JAMA Network Open. It analyzed electronic health records.
The issues included delays in speech and language, psychological development, motor function, and intellectual abilities.
Those issues can be associated with autism among older children, but “it’s way too soon to reliably diagnose autism” in the children studied, Roy Perlis, MD, told NPR. Dr Perlis is a coauthor of the report and a psychiatrist at Massachusetts General Hospital.
“All we can hope to detect at this point are more subtle sorts of things like delays in language and speech, and delays in motor milestones,” he said. “Most children of moms who have COVID during pregnancy won’t have neurodevelopmental consequences even if there is some increase in risk.”
Other studies have shown that maternal infections can affect fetal brain development, especially in boys, NPR reported.
“If a mom had SARS-CoV-2 infection in pregnancy and had a male child, her 12-month-old was 94% more likely to have any neurodevelopmental diagnosis,” said Andrea Edlow, MD, lead author and a maternal-fetal medicine specialist at Massachusetts General Hospital.
The virus that causes COVID-19 usually does not infect a fetus, she said. The risk to a fetus seems to come from the mother’s immune response, not from the infection.
JAMA Netw Open. 2023;6(3):e234415.[1]
